Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 5/2017

01-10-2017 | Myeloproliferative Neoplasms (B Stein, Section Editor)

Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

Authors: Kim-Hien T. Dao, Jeffrey W. Tyner, Jason Gotlib

Published in: Current Hematologic Malignancy Reports | Issue 5/2017

Login to get access

Abstract

Purpose of Review

We reviewed recent diagnostic and therapeutic progress in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients.

Recent Findings

Recent genetic data in CNL and aCML prompted modifications to the World Health Organization (WHO) diagnostic criteria, which have improved our understanding of how CNL and aCML are different diseases despite sharing common findings of peripheral granulocytosis and marrow myeloid hyperplasia. The overlap of recurrently mutated genes between aCML and CMML support considering CSF3R-T618I mutated cases as a distinct entity, either as CNL or CNL with dysplasia. Ongoing preclinical and clinical studies will help to further inform the therapeutic approach to these diseases.

Summary

Our understanding of CNL and aCML has greatly advanced over the last few years. This will improve clarity for the diagnosis of these diseases, provide a strategy for risk stratification, and guide risk-adapted therapy.
Literature
1.
•• Elliott MA, Tefferi A. Chronic neutrophilic leukemia 2016: update on diagnosis, molecular genetics, prognosis, and management. Am J Hematol. 2016;91(3):341–9. Summary of expected changes to WHO CNL and aCML diagnostic criteria CrossRefPubMed
2.
•• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. Summary of expected changes to WHO CNL and aCML diagnostic criteria CrossRefPubMed
3.
Mc Lornan DP, Percy MJ, Jones AV, Cross NC, Mc Mullin MF. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica. 2005;90(12):1696–7.PubMed
4.
Lea NC, Lim Z, Westwood NB, Arno MJ, Gaken J, Mohamedali A, et al. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia. Leukemia. 2006;20(7):1324–6.CrossRefPubMed
5.
Kako S, Kanda Y, Sato T, Goyama S, Noda N, Shoda E, et al. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol. 2007;82(5):386–90.CrossRefPubMed
6.
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207–9.CrossRefPubMedPubMedCentral
7.
Gajendra S, Gupta R, Chandgothia M, Kumar L, Gupta R, Chavan SM. Chronic neutrophilic leukemia with V617F JAK2 mutation. Indian Journal of Hematology & Blood Transfusion : An Official Journal of Indian Society of Hematology and Blood Transfusion. 2014;30(2):139–42.CrossRef
8.
9.
Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122(10):1707–11.CrossRefPubMedPubMedCentral
10.
•• Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125(3):499–503. First report of recurrent ETNK1 mutations in aCML CrossRefPubMed
11.
12.
Lasho TL, Finke CM, Zblewski D, Patnaik M, Ketterling RP, Chen D, et al. Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood cancer journal. 2015;5:e275.CrossRefPubMedPubMedCentral
13.
Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19(2):313–7.CrossRefPubMed
14.
Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11):1566–8.PubMed
15.
Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research. 2013;33(4):145–53.CrossRef
16.
Hasselbalch HC. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4(6):637–55.CrossRefPubMed
17.
Meyer S, Feremans W, Cantiniaux B, Capel P, Huygen K, Dicato M. Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia. Am J Hematol. 1993;43(4):307–9.CrossRefPubMed
18.
19.
Zhang X, Pan J, Guo J. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon alpha-2b. Acta Haematol. 2013;130(1):44–6.CrossRefPubMed
20.
Yassin MA, Kohla S, Al-Sabbagh A, Soliman AT, Yousif A, Moustafa A, et al. A case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2a. Clinical Medicine Insights Case Reports. 2015;8:33–6.PubMedPubMedCentral
21.
Choi IK, Kim BS, Lee KA, Ryu S, Seo HY, Sul H, et al. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report. Am J Hematol. 2004;77(4):366–9.CrossRefPubMed
22.
Shi J, Ni Y, Li J, Qiu H, Miao K. Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: a case report and literature review. Oncol Lett. 2015;9(5):2208–10.PubMedPubMedCentral
23.
Jiang H, Wu Z, Ren LI, Tao D, Tong H. Decitabine for the treatment of atypical chronic myeloid leukemia: a report of two cases. Oncol Lett. 2016;11(1):689–92.PubMed
24.
Tong X, Li J, Zhou Z, Zheng D, Liu J, Su C. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. Leukemia & Lymphoma. 2015;56(6):1911–3.CrossRef
25.
•• Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–90. CSF3R -T618I first reported as a common oncogenic driver in CNL and some aCML CrossRefPubMedPubMedCentral
26.
Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, et al. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 2014;3(2):67–9.CrossRefPubMedPubMedCentral
27.
Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia. 2014;28(6):1363–5.CrossRefPubMed
28.
Ammatuna E, Eefting M, van Lom K, Kavelaars FG, Valk PJ, Touw IP. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. Ann Hematol. 2015;94(5):879–80.CrossRefPubMed
29.
Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, et al. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematologica. 2017;102(5):e207–e9.CrossRefPubMedPubMedCentral
30.
Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Ann Hematol. 2016;95(7):1197–200.CrossRefPubMed
31.
Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, et al. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica. 2017;102(6):e238–e40.CrossRefPubMedPubMedCentral
32.
Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, et al. Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia. Cureus. 2015;7(12):e414.PubMedPubMedCentral
33.
Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, et al. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. Eur J Haematol. 2014;92(3):189–94.CrossRefPubMed
34.
Lim SN, Lee JH, Lee JH, Kim DY, Kim SD, Kang YA, et al. Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms. Blood Research. 2013;48(3):178–84.CrossRefPubMedPubMedCentral
35.
•• Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M, et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant. 2004;34(12):1047–50. Only case series documenting outcomes after allogeneic stem cell transplantation in aCML CrossRefPubMed
36.
•• Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27(9):1870–3. CSF3R -T618I reported as a highly specific oncogenic driver in CNL CrossRefPubMedPubMedCentral
37.
• Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica. 2014;99(12):e244–6. Compares specific mutations in CNL, aCML, and CMML CrossRefPubMedPubMedCentral
38.
• Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645–51. Describes distinct features between aCML and MDS/MPN unclassifiable in a large data set CrossRefPubMedPubMedCentral
39.
Dao KH, Tyner JW. What’s different about atypical CML and chronic neutrophilic leukemia? Hematology American Society of Hematology Education Program. 2015;2015:264–71.PubMedPubMedCentral
40.
Dincol G, Nalcaci M, Dogan O, Aktan M, Kucukkaya R, Agan M, et al. Coexistence of chronic neutrophilic leukemia with multiple myeloma. Leukemia & Lymphoma. 2002;43(3):649–51.CrossRef
41.
Standen GR, Jasani B, Wagstaff M, Wardrop CA. Chronic neutrophilic leukemia and multiple myeloma. An association with lambda light chain expression. Cancer. 1990;66(1):162–6.CrossRefPubMed
42.
Standen GR, Steers FJ, Jones L. Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M27 beta. J Clin Pathol. 1993;46(4):297–8.CrossRefPubMedPubMedCentral
43.
Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, et al. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leukemia & Lymphoma. 2016;57(4):927–34.CrossRef
44.
Tursz T, Flandrin G, Brouet JC, Seligmann M. Coexistence of a myeloma and a granulocytic leukemia in the absence of any treatment. Study of 4 cases. Nouv Rev Fr Hematol. 1974;14(6):693–704.PubMed
45.
Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer. 2017;17(7):425–40.CrossRefPubMed
46.
Cui YJ, Jiang Q, Liu JQ, Li B, Xu ZF, Qin TJ, et al. The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia. Zhonghua xueyexue zazhi. 2017;38(1):28–32.PubMed
47.
• Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, et al. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol. 2015;90(7):653–6. ASXL1 mutations and impact on prognosis in CNL CrossRefPubMed
48.
• Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27(9):1852–60. Survey of SETBP1 mutations among aCML and MDS/MPN subtypes CrossRefPubMed
49.
50.
Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92(6):542-48. https://​doi.​org/​10.​1002/​ajh.​24722.
51.
Tefferi A, Elliott M, Pardanani A. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. Curr Opin Hematol. 2015;22(2):171–6.CrossRefPubMed
52.
•• Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18–24. First report of recurrent SETBP1 mutations in aCML CrossRefPubMed
53.
Muramatsu H, Makishima H, Maciejewski JP. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol. 2012;39(1):67–73.CrossRefPubMedPubMedCentral
54.
• Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016;30(4):906–13. Survey of mutations observed in CMML CrossRefPubMed
55.
•• Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013;122(22):3628–31. Animal model confirming CSF3R -T618I mutation is oncogenic CrossRefPubMedPubMedCentral
56.
•• Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, et al. The Colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2016;22(3):757–64. Animal model confirming CSF3R -T640N mutation is oncogenic CrossRef
57.
Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. J Biol Chem. 2014;289(9):5820–7.CrossRefPubMedPubMedCentral
58.
Plo I, Zhang Y, Le Couedic JP, Nakatake M, Boulet JM, Itaya M, et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med. 2009;206(8):1701–7.CrossRefPubMedPubMedCentral
59.
60.
Dong F, Qiu Y, Yi T, Touw IP, Larner AC. The carboxyl terminus of the granulocyte colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia/acute myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation. Journal of Immunology (Baltimore, Md: 1950). 2001;167(11):6447–52.CrossRef
61.
van de Geijn GJ, Gits J, Aarts LH, Heijmans-Antonissen C, Touw IP. G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact. Blood. 2004;104(3):667–74.CrossRefPubMed
62.
Kunter G, Woloszynek JR, Link DC. A truncation mutant of Csf3r cooperates with PML-RARalpha to induce acute myeloid leukemia in mice. Exp Hematol. 2011;39(12):1136–43.CrossRefPubMedPubMedCentral
63.
•• Rohrabaugh S, Kesarwani M, Kincaid Z, Huber E, Leddonne J, Siddiqui Z, et al. Enhanced MAPK signaling is essential for CSF3R-induced leukemia. Leukemia. 2017;31(8):1770-78. https://​doi.​org/​10.​1038/​leu.​2016.​376.. MAPK signaling is involved in the pathogenesis of membrane-proximal CSF3R mutations.
64.
• Shou LH, Cao D, Dong XH, Fang Q, Wu Y, Zhang Y, et al. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: a meta-analysis. PLoS One. 2017;12(2):e0171608. Meta-analysis of SETBP1 mutations and impact on prognosis CrossRefPubMedPubMedCentral
65.
•• Elliott MA, Dewald GW, Tefferi A, Hanson CA. Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia. 2001;15(1):35–40. Pathologic and cytogenetic features of CNL before molecular profiling of CNL was achieved CrossRefPubMed
Metadata
Title
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
Authors
Kim-Hien T. Dao
Jeffrey W. Tyner
Jason Gotlib
Publication date
01-10-2017
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 5/2017
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0413-y

Other articles of this Issue 5/2017

Current Hematologic Malignancy Reports 5/2017 Go to the issue

Myeloproliferative Neoplasms (B Stein, Section Editor)

Familial MPN Predisposition

Myelodysplastic Syndromes (M Savona, Section Editor)

Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times

Myelodysplastic Syndromes (M Savona, Section Editor)

Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics

Myeloproliferative Neoplasms (B Stein, Section Editor)

Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis

Myeloproliferative Neoplasms (B Stein, Section Editor)

Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender

Myelodysplastic Syndromes (M Savona, Section Editor)

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits